Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046926 | 0.81 | GPR35 (0.46) | CYP3A4TSHRMAPTCYP1A2HPGD | |
| SCHEMBL1891926 | 0.81 | TSHR (0.44) | CYP3A4TSHRMAPTCYP1A2HPGD | |
| SCHEMBL1822058 | 0.81 | ALDH1A1 (0.46) | CYP3A4TSHRLMNAMAPTCYP1A2 | |
| SCHEMBL3036984 | 0.81 | GPR35 (0.46) | CYP3A4TSHRLMNAMAPTCYP1A2 | |
| SCHEMBL6282528 | 0.81 | TSHR (0.42) | CYP3A4TSHRHPGDGPR35ALDH1A1 | |
| SCHEMBL1356676 | 0.78 | ALDH1A1 (0.47) | CYP3A4TSHRLMNAMAPTGRIN2D | |
| SCHEMBL7228772 | 0.76 | TSHR (0.41) | CYP3A4TSHRLMNAMAPTCYP1A2 | |
| SCHEMBL5581181 | 0.75 | MEN1 (0.35) | TSHRLMNAALDH1A1HSD17B10TDP1 | |
| SCHEMBL10903901 | 0.73 | VCAM1 (0.34) | MAPTCYP1A2HPGDGRIA1GRIA2 | |
| SCHEMBL4577560 | 0.71 | ATM (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | claimed |
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| CN-101573341-A | Imidazolidinone Kv1.5 potassium channel inhibitors | WYETH CORP (US) | 2009-11-04 | — | — | CN | disclosed |
| CN-101472924-A | KV1.5 potassium channel inhibitors | WYETH CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| EP-2035392-A1 | IMIDAZOLE KV1. 5 POTASSIUM CHANNEL INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2035420-A2 | KV1.5 POTASSIUM CHANNEL INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7504517-B2 | Kv1.5 potassium channel inhibitors | WYETH (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090012009-A1 | Composition and Method for Treating Inflammatory Disease | PURDUE RESEARCH FOUNDATION | 2009-01-08 | — | — | US | disclosed |
| EP-1069126-B1 | TRIAZOLOPURINE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVES, ADENOSINE A3 RECEPTOR COMPATIBILIZING AGENT, AND ASTHMATIC REMEDY | OTSUKA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-0638075-B1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-6288070-B1 | Triazolopurine derivatives, medicinal composition containing the derivatives, adenosine A3 receptor compatibilizing agent, and asthmatic remedy | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-1069126-A1 | TRIAZOLOPURINE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVES, ADENOSINE A3 RECEPTOR COMPATIBILIZING AGENT, AND ASTHMATIC REMEDY | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| US-4138554-A | 7-[D-α-(4-Hydroxy-1,5-naphthyridine-3-carboxamido)-α-phenyl (and p-hydroxyphenyl)acetamido]-3-carbamoyloxymethyl-3-cephem-4-carboxylic acids | BRISTOL-MYERS COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | CYP3A4 2091/4885TSHR 3023/4885LMNA 4046/4885 |
| US-20090012009-A1 | Composition and Method for Treating Inflammatory Disease | CYP24A1, CYP7B1, CYP2R1 | CYP3A4 348/4885TSHR 4384/4885LMNA 2442/4885 |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | CYP3A4 1139/4885TSHR 2546/4885LMNA 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.